Results 101 to 110 of about 5,123 (202)

Characterization of Neutropenia in Preterm Neonates Following Administration of Darbepoetin Alfa. [PDF]

J Pediatr Pharmacol Ther, 2023
Andrews N, Friedman S, Dunham M, Dean R, Chabra S.   +4 more
europepmc   +1 more source

Exacerbation of Diabetic Retinopathy following Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor Administration: A Case Report

Case Reports in Ophthalmology
Introduction: Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, used in the treatment of renal anemia, hold the potential to increase the production of vascular endothelial growth factors.
Nobuaki Ariyoshi, Fumiaki Higashijima, Makiko Wakuta, Tadahiko Ogata, Manami Ohta, Kazuhiro Kimura   +5 more
doaj   +1 more source

Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial. [PDF]

Clin Exp Nephrol, 2023
Maruyama S, Kurasawa S, Hayashi T, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T, PREDICT Investigators.   +11 more
europepmc   +1 more source

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO₂TECT Randomized Clinical Trial of ESA-Naïve Patients. [PDF]

Kidney Med, 2023
Winkelmayer WC, Arnold S, Burke SK, Chertow GM, Eckardt KU, Jardine AG, Lewis EF, Luo W, Matsushita K, McCullough PA, Minga T, Parfrey PS.   +11 more
europepmc   +1 more source

Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia [PDF]

, 2018
Introduction: Anaemia during chemotherapy is often left untreated. Erythropoiesis-stimulating agents are frequently used to treat overt anaemia.
Biedermann, Beat, Hermann, Richard, Leyvraz, Serge, Lüthi, François, Monnerat, Christian, Müller, Emilie, Pless, Miklos   +6 more
core  

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO₂TECT Randomized Clinical Trial of ESA-Treated Patients. [PDF]

Kidney Med, 2023
Parfrey PS, Burke SK, Chertow GM, Eckardt KU, Jardine AG, Lewis EF, Luo W, Matsushita K, McCullough PA, Minga T, Winkelmayer WC.   +10 more
europepmc   +1 more source

Darbepoetin-alfa [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Iron status and erythropoiesis response to darbepoetin alfa in dogs with chronic kidney disease. [PDF]

J Vet Med Sci, 2021
Bhamarasuta C, Premratanachai K, Mongkolpinyopat N, Yothapand P, Vejpattarasiri T, Dissayabutra T, Trisiriroj M, Sutayatram S, Buranakarl C.   +8 more
europepmc   +1 more source

An Exploratory Analysis of Pharmaceutical Price Disparities and Their Implications Among Six Developed Nations [PDF]

In our study of 43 drugs, prescription drug prices in several wealthy nations (Australia, Canada, France, Germany, and the U.K.) were much lower than in the U.S. on average, well below relative per capita GDP. There was relatively little difference among
Calfee, John E., DuPr�, Elizabeth, Villarreal, Mario   +2 more
core   +1 more source

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial. [PDF]

Int J Hematol, 2022
Morita Y, Nannya Y, Ichikawa M, Hanamoto H, Shibayama H, Maeda Y, Hata T, Miyamoto T, Kawabata H, Takeuchi K, Tanaka H, Kishimoto J, Miyano S, Matsumura I, Ogawa S, Akashi K, Kanakura Y, Mitani K.   +17 more
europepmc   +1 more source